Yukimatsu Toh

The paper develops RSPO2-based peptibody-drug conjugates that target LGR4/5/6 receptors, showing potent anti-tumor activity in colorectal cancer and neuroblastoma models.

This study shows cetuximab increases LGR5 expression and improves the efficacy of LGR5-targeting ADCs in colorectal cancer models.

This study develops and tests a camptothecin analog conjugate targeting LGR4/5/6 in CRC models, showing potent anti-tumor activity with minimal toxicity.